Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

farmalinx pty ltd - sulfur (s) as wettable sulfur - dry flowable - sulfur (s) as wettable sulfur mineral-sulfur active 800.0 g/kg - miticide - citrus | grape - table | grapevine | kiwi fruit | mangosteen | ornamental | pome fruit | rambutan | stone fruit (see label for e - bean or broad bean rust- u. viciae-fabae | bean spider mite | black spot - venturia spp. | brown citrus rust mite | brown rot - monilinia spp. | carmine mite | citrus bud mite | citrus melanose | citrus rust mite or maori mite | grapeleaf blister mite | lichen | mite | moss | powdery mildew | powdery mildew on grapevine | powdery mildew on pome | rust - uromyces spp. | stone fruit rust | tomato russet mite | vine mite | white louse scale | black spot (scab) | blossom blight | brown citrus mite | citrus rust mites | citrus snow scale | red spider mite | rust mite | spider mite | tomato mite (47236) | transzchelia pruni-spinosae | two-spotted mite | two-spotted spider mite | uromyces phaseoli var. typica | vineleaf blister mite

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

kenso corporation (m) sdn. bhd. - sulphur(s) present as elemental sulphur - water dispersible granule - sulphur(s) present as elemental sulphur mineral-sulphur active 800.0 g/kg - mixed function pesticide - citrus | grape | grape - wine | kiwi fruit | mangosteen | nectarine | ornamental crops | peach | plum | pome fruit | rambutan | - bean spider mite | black spot - colletotrichum acutatum | blossom blight - monilinia laxa | brown citrus rust mite | brown rot | bud mite | carmine mite | citrus melanose | citrus rust mite or maori mite | grapeleaf blister mite | lichen | mite | moss | powdery mildew | powdery mildew - oidium spp. | rust | rust - uromyces appendiculatus | tomato russet mite | vine mite | white louse scale | anthracnose | bean rust | brown citrus mite | brown rot | citrus rust mites | citrus snow scale | red spider mite | rust mite | spider mite | tomato mite (47236) | two-spotted mite | two-spotted spider mite | vineleaf blister mite

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

upl australia pty ltd - sulfur; sulfur - water dispersible granule - sulfur mineral-sulfur active 800.0 g /kg; sulfur mineral-sulfur active 800.0 g/kg - fungicide - citrus | grape - table | grape - wine | grapevine | kiwi fruit | mangosteen | ornamental | pome fruit | rambutan | stone fruit ( - bean or broad bean rust- u. viciae-fabae | bean spider mite | black spot - venturia spp. | brown citrus rust mite | brown fruit rot - monilinia fructicola | bud mite | citrus bud mite | citrus melanose | citrus rust mite or maori mite | grapeleaf blister mite | mite | powdery mildew | powdery mildew - podosphaera leucotricha | powdery mildew - sphaerotheca spp. | powdery mildew on grapevine | powdery mildew on strawberry | prune rust | rust - uromyces spp. | rust mite | tomato russet mite | two spotted mite | vine mite | white louse scale | black spot (scab) | blossom blight | brown citrus mite | brown rot | citrus rust mites | citrus snow scale | red spider mite | rust mite | sphaerotheca macularis | spider mite | tomato mite (47236) | two-spotted mite | two-spotted spider mite | uromyces phaseoli var. typica | vineleaf blister mite

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

amgrow pty ltd - sulfur (s) as wettable sulfur - wettable powder - sulfur (s) as wettable sulfur mineral-sulfur active 800.0 g/kg - fungicide - citrus fruit or tree | grape | ornamental | pome fruit | stone fruit (see label for exceptions) | vegetable (see label for excep - bean spider mite | black spot | brown citrus rust mite | brown rot - monilinia spp. | carmine mite | citrus bud mite | citrus rust mite or maori mite | grapeleaf blister mite | powdery mildew | powdery mildew on grapevine | powdery mildew on pome | rust | stone fruit rust | tomato russet mite | vine mite | white louse scale | blossom blight | brown citrus mite | citrus rust mites | citrus snow scale | red spider mite | rust mite | scab | spider mite | tomato mite (47236) | transzchelia pruni-spinosae | two-spotted mite | two-spotted spider mite | vineleaf blister mite

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - clobetasol propionate 0.5 mg/g - topical cream - 0.5 mg/g - active: clobetasol propionate 0.5 mg/g excipient: cetostearyl alcohol chlorocresol citric acid monohydrate glycerol glyceryl 1-monostearate propylene glycol purified water sodium citrate white beeswax - treatment of resistant dermatoses such as psoriasis (excluding widespread plaque psoriasis), recalcitrant eczemas, lichen planus and discoid lupus eyrthematosus and other skin conditions which do not respond satisfactorily to less active steroids.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - clobetasol propionate 0.5 mg/g - topical ointment - 0.5 mg/g - active: clobetasol propionate 0.5 mg/g excipient: propylene glycol sorbitan sesquioleate white soft paraffin - treatment of resistant dermatoses such as psoriasis (excluding widespread plaque psoriasis), recalcitrant eczemas, lichen planus and discoid lupus eyrthematosus and other skin conditions which do not respond satisfactorily to less active steroids.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methylprednisolone acetate, quantity: 40 mg/ml - injection, suspension - excipient ingredients: hydrochloric acid; macrogol 3350; miripirium chloride; sodium chloride; sodium hydroxide - indications as at 17 november 2004: a.for intramuscular administration. when oral therapy is not feasible and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of depo-nisolone is indicated as follows: 1. endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone acetate is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone acetate is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used). preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. congenital adrenal hyperplasia. hypercalcaemia associated with cancer. non-suppurative thyroiditis. 2. rheumatic disorders. as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: post-traumatic osteoarthritis. epicondylitis. synovitis of osteoarthritis. acute non-specific tenosynovitis. rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). acute gouty arthritis. psoriatic arthritis. ankylosing spondylitis. acute and subacute bursitis. 3. collagen diseases. during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus. acute rheumatic carditis. systemic dermatomyositis (polymyositis). 4. dermatological diseases. pemphigus. bullous dermatitis herpetiformis. severe erythema multiforme (stevens-johnson syndrome). severe seborrhoeic dermatitis. exfoliative dermatitis. severe psoriasis. mycosis fungoides. 5. allergic states. control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: bronchial asthma. drug hypersensitivity reactions. contact dermatitis.urticarial transfusion reactions. atopic dermatitis. acute non-infectious laryngeal oedema (adrenaline is the drug of first choice). serum sickness. 6. ophthalmic diseases. severe acute and chronic allergic and inflammatory processes involving the eye, such as: herpes zoster ophthalmicus. sympathetic ophthalmia. iritis, iridocyclitis. anterior segment inflammation. chorioretinitis. allergic conjunctivitis. diffuse posterior uveitis. allergic corneal marginal ulcers. optic neuritis. keratitis. 7. gastrointestinal diseases. to tide the patient over a critical period of the disease in: ulcerative colitis (systemic therapy). regional enteritis (systemic therapy). 8. respiratory diseases.symptomatic sarcoidosis. berylliosis. fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculous chemotherapy. aspiration pneumonitis. loeffler's syndrome not manageable by other means. 9. haematological disorders. acquired (autoimmune) haemolytic anaemia. erythroblastopenia (rbc anaemia). secondary thrombocytopenia in adults. congenital (erythroid) hypoplastic anaemia. 10. neoplastic diseases. for palliative management of: leukaemias and lymphomas in adults. acute leukaemia in childhood. 11. oedematous states. to induce diuresis or remission of proteinuria in the nephrotic syndrome without uraemia of the idiopathic type or that due to lupus erythematosus. 12. miscellaneous. tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculous chemotherapy. trichinosis with neurological or myocardial involvement. b. for intra-articular or soft tissue administration depo-nisolone is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis. epicondylitis. rheumatoid arthritis. acute non-specific tenosynovitis. acute and subacute bursitis. post-traumatic osteoarthritis. acute gouty arthritis. c. for intralesional administration. depo-nisolone is indicated for intralesional use in the following conditions: keloids.discoid lupus erythematosus. necrobiosis lipoidica diabeticorum. alopecia areata. localised hypertrophic, infiltrated inflammatory lesions of licen planus, psoriatic plaques, granuloma annulare and lichen simplex chronicus (neurodermatitis). depo-nisolone may also be useful in cystic tumours of an aponeurosis or tendon (ganglia).

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - betamethasone acetate, quantity: 3 mg/ml (equivalent: betamethasone, qty 5.7 mg/ml); betamethasone sodium phosphate, quantity: 3.9 mg/ml - injection, suspension - excipient ingredients: disodium edetate; monobasic sodium phosphate; water for injections; dibasic sodium phosphate; benzalkonium chloride - celestone chronodose is indicated in the treatment of both severe and moderate conditions in acute and chronic self-limiting diseases responsive to systemic corticosteroid therapy and is especially useful in patients for whom treatment with oral corticosteroid medication is not feasible. representative conditions: rheumatic disorders: rheumatoid arthritis, acute and subacute bursitis, epicondylitis, acute non-specific tenosynovitis, myositis, fibrositis, tendonitis, psoriatic arthritis. collagen diseases: systemic lupus erythematosus, scleroderma, dermatomyositis. allergic states: status asthmaticus, chronic bronchial asthma, seasonal or perennial allergic rhinitis, severe allergic bronchitis, contact dermatitis, atopic dermatitis, hypersensitivity reactions to drug and insect bites. dermatologic conditions: localised, hypertrophic infiltrated lesions of lichen planus, psoriatic plaques, granuloma annulare and lichen simplex chronicus(neurodermatitis). keloids, discoid lupus erythematosus, necrobiosis lipoidi

Israel - English - Ministry of Health

truemed ltd. - estradiol as hemihydrate; norethisterone acetate - patches - estradiol as hemihydrate 3.2 mg; norethisterone acetate 11.2 mg - estradiol, combinations - estradiol, combinations - hormone replacement therapy for the relief of menopausal symptoms.

Israel - English - Ministry of Health

rafa laboratories ltd - minocycline as hydrochloride - capsules - minocycline as hydrochloride 50 mg - minocycline - minocycline - treatment of infections caused by minocycline-sensitive micro-organisms including acne, gonorrhea and prophylaxis of asymptomatic meningococcal carrier.